ArticleCancer management and research2026
Prognostic Impact of the Systemic Immune-Inflammation Index in Unresectable Hepatocellular Carcinoma Undergoing Second-Line Combination Therapy: A Multicenter Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with advanced hepatocellular carcinoma (HCC) who progress after first-line systemic therapy face a poor prognosis. This study evaluated the prognostic value of the baseline systemic immune-inflammation index (SII) in patients with unresectable HCC receiving second-line regorafenib, immune checkpoint inhibitors (ICIs), and transarterial chemoembolization (TACE). Methods: This multicenter, retrospective study included a cohort of 118 patients with unresectable HCC who experienced disease progression on first-line systemic treatment. To avoid the optimism bias and overfitting associated with data-derived binary cut-offs, the baseline SII was log-transformed and rigorously evaluated as a continuous variable. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were analyzed using multivariate Cox proportional hazards models adjusted for key clinical confounders. Results: In the multivariate analysis, the continuous log-transformed SII emerged as an independent prognostic factor. Each 1-unit increase in the log-SII was significantly associated with a 33% increased risk of disease progression (Adjusted Hazard Ratio [HR] = 1.33, 95% CI: 1.06-1.68, P = 0.015) and a 50% increased risk of overall mortality (Adjusted HR = 1.50, 95% CI: 1.08-2.09, P = 0.017). Subgroup analyses confirmed the consistency of these prognostic trends regardless of the regorafenib starting dose or the specific type of ICI administered. Notably, while baseline SII levels were not associated with objective response rates (ORR), they were significantly associated with an increased risk of severe treatment-related adverse events, underscoring its role as both a prognostic biomarker and a potential indicator of treatment tolerance. Conclusion: Baseline SII, when evaluated as a continuous variable, is a statistically significant and non-invasive prognostic biomarker for patients with unresectable HCC receiving second-line triple therapy. While its discriminatory ability as a standalone tool is modest, it serves as a useful clinical parameter for risk stratification when integrated with established hepatic and tumor burden indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.